Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...
Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
Can we afford the cost of newly approved targeted therapeutics in the management...
Dr Sana Al Sukhun - Al Hyatt Oncology Practice, Amman
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
Comment: Dabrafenib plus trametinib significantly increases overall response rat...
Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
ASCO 2022: Latest developments in mHSPC and mCRPC
Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip